GlassScriptPhysician profile
Jonathan Ian Weltz
NPI 1376076158
$10,327.13
in general payments reported to CMS, 2019-2025
40 companies · $8,479 in 2025
The $8,479 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $348 · 2024: $1,374 · 2025: $8,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,735 · Food and Beverage: $3,717 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Consulting Fee: $650 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,734.85 |
| Food and Beverage | $3,717.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Consulting Fee | $650.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,069.96 | 2025 | |
| Karyopharm Therapeutics INC. | $2,887.57 | 2025 | Xpovio |
| Daiichi Sankyo INC. | $897.52 | 2024-2025 | Vanflyta, Enhertu, Datroway |
| Janssen Biotech, INC. | $302.07 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Pfizer INC. | $261.35 | 2023-2025 | |
| Kite Pharma, INC. | $245.11 | 2023-2024 | Yescarta |
| Genzyme Corporation | $197.41 | 2024-2025 | |
| Incyte Corporation | $171.58 | 2024-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $168.67 | 2024-2025 | Enhertu, Tagrisso |
| Glaxosmithkline, LLC. | $166.93 | 2023-2025 | Ojjaara |
| Genentech USA, INC. | $159.96 | 2024-2025 | Tecentriq, Itovebi, Phesgo |
| Amgen INC. | $125.00 | 2023 | Lumakras |
| Seagen INC. | $125.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $123.92 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $120.26 | 2023-2025 | Keytruda, Welireg |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $114.95 | 2024-2025 | Vyloy, Xospata |
| Rigel Pharmaceuticals, INC. | $92.95 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $91.78 | 2023-2025 | Opdivo, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $86.89 | 2024-2025 | Ninlaro, Alunbrig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.00 | 2025 | |
| Eisai INC. | $81.84 | 2024 | |
| Exelixis INC. | $78.64 | 2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $72.72 | 2024-2025 | Qinlock |
| Aveo Pharmaceuticals, INC. | $71.83 | 2025 | |
| Adaptive Biotechnologies Corporation | $59.46 | 2024-2025 | Clonoseq |
| Tersera Therapeutics LLC | $59.20 | 2024-2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $52.90 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $47.53 | 2024 | Verzenio, Jaypirca |
| Array Biopharma INC | $46.91 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Sobi, INC | $35.88 | 2025 | |
| Caris Mpi, INC. | $30.56 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $28.70 | 2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $26.84 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2025 | |
| Beigene USA, INC. | $21.65 | 2024 | Brukinsa |
| Emd Serono, INC. | $21.57 | 2025 | |
| Gilead Sciences, INC. | $20.18 | 2024 | |
| Celgene Corporation | $20.12 | 2024 | Pomalyst |
| Cumberland Pharmaceuticals, INC. | $19.51 | 2023 | Sancuso |
| Beone Medicines USA, INC. | $17.52 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.